Patents Examined by Daniel C Gamett
  • Patent number: 11401507
    Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 2, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
  • Patent number: 11400164
    Abstract: The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: August 2, 2022
    Assignees: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
  • Patent number: 11397178
    Abstract: The present invention describes methods of monitoring the efficacy of a pulmonary fibrosis, such as idiopathic pulmonary, fibrosis (IPF), treatment. Also described are methods of predicting the progression of IPF. These methods are based, at least in part, on the presence and/or level of CCR10-positive cells.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: July 26, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Cory Hogaboam, David Habiel
  • Patent number: 11390849
    Abstract: The present invention refers to a method for the production of activated CD3-CD56+ NK cells, activated CD3-CD56 NK+ cells obtainable with the method, their use, in particular for the treatment of a tumor, preferably a hepatocellular carcinoma (HCC), for use in the treatment and/or prevention of an HCV infection, for use in the treatment and/or prevention of a post-liver transplant HCV reinfection, or for use for prevention of a post-liver transplant HCC recurrence. The invention also concerns pharmaceutical compositions including the activated CD3-CD56+ NK cells.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: July 19, 2022
    Assignees: FONDAZIONE RI.MED, ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE . ISMETT
    Inventor: Ester Badami
  • Patent number: 11369639
    Abstract: The present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: June 28, 2022
    Assignee: ProKidney
    Inventors: Joydeep Basu, Kelly Guthrie, Dominic Justewicz, Teresa Burnette, Andrew Bruce, Russell W. Kelley, John W. Ludlow
  • Patent number: 11351196
    Abstract: Provided herein are methods and customized media compositions for culturing CIK NKT cells.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: June 7, 2022
    Assignee: ImmunityBio, Inc.
    Inventors: Rohit Duggal, Ranjeet Sinha
  • Patent number: 11339220
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: May 24, 2022
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson
  • Patent number: 11331379
    Abstract: The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: May 17, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, James Lo
  • Patent number: 11332501
    Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: May 17, 2022
    Assignee: MOLECULAR PARTNERS AG
    Inventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
  • Patent number: 11324726
    Abstract: Provided in the present invention are uses of a compound as represented by formula I in preparing a stem cell apoptosis antagonist. Also provided are uses of the compound as represented by formula I in preparing a medicament for preventing or treating cell apoptosis-related diseases, and a culturing method employing the compound as represented by formula I for stem cell culturing. The compound as represented by formula I is (I).
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 10, 2022
    Assignee: BEIJING NORMAL UNIVERSITY
    Inventors: Mei Han, Jinhua Wen, Ying Sun, Huajun Li
  • Patent number: 11318202
    Abstract: There is disclosed compositions and methods relating to or derived from anti-WISP1 antibodies. More specifically, there is disclosed fully human antibodies that bind WISP1, WISP1-binding fragments and derivatives of such antibodies, and WISP1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having WISP1 related disorders or conditions. There is also disclosed a method for treating or preventing various cancers or inflammatory diseases and various diseases of the heart, bone/joints or lung.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: May 3, 2022
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Gunnar F. Kaufmann
  • Patent number: 11312781
    Abstract: The present invention relates to antigen binding molecules, including antibodies, fragments, and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14). The present invention also relates to methods of use of such antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: April 26, 2022
    Assignee: Capella BioScience Ltd.
    Inventor: Steve Holmes
  • Patent number: 11304982
    Abstract: Disclosed herein are methods and compositions for stimulating angiogenesis, using cells descended from marrow adherent stromal cells that have been transfected with sequences encoding a Notch intracellular domain. Applications of these methods and compositions include treatment of ischemic disorders such as stroke.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: April 19, 2022
    Assignee: AtriCure, Inc.
    Inventors: Monique Dao, Ciara Tate, Casey C. Case
  • Patent number: 11299554
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 12, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rumana Rashid, John Desjarlais
  • Patent number: 11285174
    Abstract: The present invention relates to alternatively activated macrophages (AAMs) for use in the treatment of liver injury and methods of treating and preventing liver injury using AAMs.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: March 29, 2022
    Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventors: Stuart Forbes, Philip Starkey Lewis, Lesley Forrester
  • Patent number: 11279915
    Abstract: Provided herein are, inter alia, methods, compositions, and kits for producing adipocyte populations such as beige adipocyte populations. Also included are methods and compositions for increasing the level of adipocyte populations (e.g., beige adipocyte populations) in a subject, as well as methods and compositions for treating subjects who are overweight, obese, or who have diabetes.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 22, 2022
    Assignee: Maine Medical Center Research Institute
    Inventor: Aaron C. Brown
  • Patent number: 11278569
    Abstract: An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: March 22, 2022
    Assignee: PAEAN BIOTECHNOLOGY INC.
    Inventors: Kyuboem Han, Youngjun Lee
  • Patent number: 11279760
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: March 22, 2022
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson
  • Patent number: 11274133
    Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: March 15, 2022
    Assignee: PHILOGEN S.P.A.
    Inventors: Roberto De Luca, Francesca Pretto, Sarah Wulhfard
  • Patent number: 11246890
    Abstract: Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: February 15, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Tzuhua Dennis Lin, Stuart B. Goodman, Sai-Wen Tang, Everett Hurteau Meyer, Magdiel Pérez Cruz